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Deciphering translation is of paramount importance for the understanding of many diseases, 
and antibiotics played a pivotal role in this endeavour. Blasticidin S (BlaS) targets translation 
by binding to the peptidyl transferase center of the large ribosomal subunit. Using biochemical, 
structural, and cellular approaches, we show here that BlaS inhibits both translation elongation 
and termination in Mammalia. Bound to mammalian terminating ribosomes, BlaS distorts the 
3’CCA tail of the P-site tRNA to a larger extent than previously reported for bacterial 
ribosomes, thus delaying both, peptide bond formation and peptidyl-tRNA hydrolysis. While 
BlaS does not inhibit stop codon recognition by the eukaryotic release factor1 (eRF1), it 
interferes with eRF1’s accommodation into the peptidyl transferase center and subsequent 
peptide release. In human cells, BlaS inhibits nonsense-mediated mRNA decay and, at 
subinhibitory concentrations, modulates translation dynamics at premature termination 






Ribosome-targeting antibiotics are priceless tools in biochemistry and structural biology to 
dissect individual steps of translation and probe the modes of action of these antibiotics as 
well as of the factors involved in translation. A plethora of such compounds target translation 
initiation and elongation, and many of the antibiotics compromising elongation have been 
implemented in clinical practice (1). However, only very few antibiotics interfere with translation 
termination (1,2). Blasticidin S (BlaS) is an inhibitor of translation termination in bacteria (3). 
As early as in the 1960s, BlaS was known to inhibit protein synthesis in all kingdoms of life (3-
7). BlaS is a peptidyl-nucleoside antibiotic composed of a cytosine, a pyranose sugar ring, and 
an N-methyl-guanidine tail. Structures show that BlaS binds to the P-site loop formed by 
ribosomal RNA within the peptidyl transferase center in the large ribosomal subunit of 
Thermus thermophilus (3), the archaea Haloarcula marismorui (8), and Saccharomyces 
cerevisiae (9). In contrast, other antibiotics known to interfere with peptide bond formation, 
such as puromycin or anisomycin, bind to the A-site in the peptidyl transferase center and 
inhibit aminoacyl-tRNA binding in archaea and yeast (8,9). 
Structures of bacterial translating ribosomes showed that ribosome-bound BlaS displaces and 
deforms the 3’CCA tail of P-site tRNA and distorts release factor 1 (RF1) binding in the A-site 
of the peptidyl transferase center, thereby preventing peptidyl-tRNA hydrolysis (3,10). BlaS 
also interferes with aminoacyl-tRNA binding to the ribosomal A-site and subsequent peptidyl 
transfer. However, peptide release is inhibited at considerably lower concentrations than 
peptide bond formation, and thus BlaS preferentially inhibits translation termination in bacteria 
(3,10). Since in S. cerevisiae BlaS binding to the P-site loop in the peptidyl transferase center 
was found to be conserved, inhibition of translation termination by BlaS was suggested to be 
the conserved in eukaryotes and in bacteria (9). 
In eukaryotic cells, translation termination is monitored by nonsense-mediated mRNA decay 
(NMD), a conserved eukaryotic mRNA surveillance pathway that targets mRNAs with 
premature stop codons for degradation (11-13). Active translation is required to recognize 
such nonsense mRNAs. Consequently, inhibition of translation by antibiotics cycloheximide, 
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anisomycin or puromycin protects nonsense mRNAs from NMD (14-16). How NMD factors 
recognize nonsense mRNAs and differentiate between proper and improper termination 
remains enigmatic. According to current NMD models, translation termination at a premature 
termination codon is slow and inefficient compared to termination at a normal stop codon (11-
13,17). This has been suggested to be caused by ribosome stalling at a premature stop codon, 
possibly due to inappropriate spacing between the stop codon and the termination-promoting 
poly(A)-binding protein in the 3’-untranslated region (18,19). Furthermore, the conserved NMD 
factor UPF3B has been shown to delay translation termination in vitro in a fully reconstituted 
human translation system (20). 
Nonsense mutations constitute ~20% of all human disease-associated single-base pair 
mutations (21). In this context, compounds that specifically modulate translation termination 
enabling enrichment of terminating ribosomes, are urgently needed to better understand the 
difference between termination at normal versus premature termination codons and to design 
new treatment strategies for diseases caused by nonsense mutations. 
Here, we dissected the impact of BlaS on mammalian translation, termination and on NMD. 
Using mammalian in vitro translation systems, we show that BlaS inhibits both translation 
elongation and termination. During termination, BlaS impairs peptide release and subsequent 
ribosomal dissociation by UPF3B. Cryogenic electron microscopy (cryo-EM) of BlaS-bound 
mammalian termination complexes reveals that, in contrast to bacterial complexes, 
accommodation of eRF1 in the peptidyl transferase center is inhibited in the mammalian 
ribosome due to a substantially larger deformation of the 3’CCA tail of the P-site tRNA, which 
is also predicted to interfere with peptide bond formation. In HeLa cells, BlaS treatment does 
not promote NMD by stalling termination, but instead stabilizes the premature stop codon-
mutated mRNA. At low, sub-inhibitory concentrations BlaS increases production of the 




MATERIALS AND METHODS 
In vitro transcription and capping 
The C_Firefly LUC plasmid (22) encoding the Firefly luciferase gene was linearized by Not1 
and transcribed in vitro using the T3 MEGAscript polymerase kit (Invitrogen, #AM1338) 
following the manufacturer’s protocol. The mRNA was purified by LiCl precipitation, and 
subsequently capped using vaccinia capping enzyme (VCE) and S-Adenosyl Methionine 
(SAM, New England Biolabs, #B9003S). Briefly, 10 µg of mRNA was heated to 65°C for 10 
mins, then transferred to ice. The capping reaction was started in reaction buffer (50 mM Tris-
HCl pH 8, 5 mM KCl, 1 mM MgCl2, 1 mM DTT) supplemented with 10 mM GTP and 2 mM 
SAM (final concentrations) with 1.6 µg VCE, incubated at 37°C for one hour, and subsequently 
the mRNA was purified by LiCl precipitation. The mRNA transcript encoding the 3xFLAG-
tagged VHP protein was generated using the pSP64_3FLAG-VHPbeta68(TAG) plasmid as a 
DNA template as described previously (23). The DNA was linearized and amplified by PCR 
with forward primer (5’-TAATACGACTCACTATAGGGAATACAAGCTTGCTTGTTCTTTTTG-
3’) annealing 100 base pairs (bp) upstream of the ORF, and reverse primer (5’-
GAGGCGGTTTGCGTATTG-3’) annealing 200 bp downstream of the TAG stop codon. In vitro 
transcription and capping were performed as described above using T7 RNA polymerase 
(New England Biolabs, #M0251S) in the place of T3 MEGAscript following the manufacturer’s 
protocol.  
Cloning of pSP64 3xFLAG-VHP-Sec61β _Y(TAG) plasmid 
For peptide release assays, a 3xFLAG-tagged VHP protein with a C-terminal tyrosine residue 
before the stop codon, in place of the original Valine, was created. The valine to tyrosine 
substitution was generated by PCR amplification of the pSP64 3xFLAG-VHP-Sec61β plasmid 
(23) to create the insert (forward primer: 5’-
TAAAGATCATGACATCGATTACAAGGATGACGATG-3’, reverse primer: 5’- 
ACAGCTATGACATGATTACGAAGCTTCTAGTATTTGAGCCCAGGTGAATCTT-3’). The 
backbone was produced by digestion of pSP64 3xFLAG-VHP-Sec61β (TAG) with Cla1 and 
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EcoR1, then Gibson ligation to assemble the final plasmid containing the tyrosine substitution 
(pSP64 3xFLAG-VHP-Sec61β (Tyr)(TAG)). 
Recombinant protein purification 
Plasmids pProEx_Htb encoding eRF1 (20) and eRF1AAQ (generated using a Q5 site-directed 
mutagenesis kit; New England Biolab #E0554S) were transformed into Escherichia coli BL21 
Star (DE3), grown in 6L of dYT until an OD600nm of 0.8, induced with 1 mM IPTG, and harvested 
after growth overnight at 20°C by centrifugation (Sorvall LYNX 6000 Superspeed Centrifuge 
(ThermoFisher) and Fiberlite™ F9-6 x 1000 LEX Fixed Angle Rotor (ThermoFisher), 5,000xg, 
10 mins, 4⁰C). Cell pellets were resuspended in 1xPBS supplemented with an additional 250 
mM NaCl, 10 mM Imidazole, 1 mM DTT, two cOmplete EDTA-free protease inhibitor cocktail 
tablets (SigmaAldrich, #11873580001), and 1 mM PMSF. Cells were lysed using a French 
Press (Constant Systems, TS 0.75kV) operating at 25,000 PSI followed by centrifugation 
(Sorvall LYNX 6000 Superspeed Centrifuge (ThermoFisher) and Fiberlite™ F21-8 x 50y 
Fixed-Angle Rotor (ThermoFisher), 45,000xg, 1 hour, 4°C). The supernatant was loaded onto 
1 mL HisTrap FF IMAC column (GE, #17531901). The column was washed with 25 column 
volumes (CV) and eRF1 eluted with a 50 CV gradient to 300 mM imidazole-containing lysis 
buffer. Eluted eRF1 was concentrated in lysis buffer lacking imidazole to a concentration of 
300 µM, flash frozen, and stored at -80°C. 
eRF3a was expressed in SF21 insect cells using the Multibac system (24) starting from the 
pFastBac_Htb plasmid as previously described (20). Cells were harvested by centrifugation 
(Sorvall LYNX 6000 Superspeed Centrifuge (ThermoFisher) and Fiberlite™ F9-6 x 1000 LEX 
Fixed Angle Rotor (ThermoFisher) 800xg, 10 min, 4°C) and pellets were resuspended in lysis 
buffer (25 mM HEPES pH 7.4, 300 mM NaCl, 10 mM imidazole, 5% glycerol) and 
supplemented with a cOmplete EDTA-free protease inhibitor cocktail tablet before being lysed 
by sonication for 3 min on time at 70% amplitude using 5/10 second on/off cycling. The lysate 
was clarified by centrifugation at 45,000xg (Sorvall LYNX 6000 Superspeed Centrifuge 
(ThermoFisher) and Fiberlite™ F21-8 x 50y Fixed-Angle Rotor (ThermoFisher) and 
supernatant incubated with 2 mL Ni-NTA superflow resin (Qiagen, #30410) for 1 hour. The 
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resin was then washed in lysis buffer containing 1 M NaCl, followed by 2X 10mL washes in 
lysis buffer and 4X 10mL elution steps with lysis buffer supplemented with 50 mM, 100 mM, 
150 mM, and 250 mM imidazole. Wash and elution fractions were analyzed by SDS-PAGE. 
eRF3a-containing fractions were diluted to 150 mM NaCl (final salt concentration) in buffer 
containing 25 mM HEPES pH 7.4, 1 mM DTT and loaded onto a 5 mL HiTrap Q XL column 
(GE, #17515901). Proteins were eluted over a 25 CV gradient from 150 to 1000 mM NaCl. 
Protein-containing fractions were analyzed by SDS PAGE and concentrated to 300 µM, flash 
frozen, and stored at -80°C. VCE was purified as previously described (25). 
In vitro translation luciferase assay 
100 ng Firefly luciferase mRNA was added to rabbit reticulocyte lysate (Green Hectares, 
Wisconsin, USA) in a reaction volume of 10 µL, as described previously (26). Blasticidin S 
(Sigma-Aldrich, #15205) was added simultaneously, and the in vitro translation reactions were 
incubated at 30°C for 30 mins. Reactions were stopped by the addition of 30 µL of 1X lysis 
buffer from the luciferase assay kit (Promega, #E1500). The luciferase activity was detected 
following the manufacturer’s protocol using a Synergy Neo2 plate reader (BioTek, Vermont, 
USA).  
Preparation of pre-termination complexes 
In vitro translation reactions were conducted using an adapted RRL system (23,27). For 
biochemical assays, [35S]-labelled pre-TCs were prepared as follows: RRL in vitro translation 
reactions were supplemented with 2 µg of mRNA, 10 µM eRF1AAQ and 0.1 mCi EasyTag™ 
[35S]-methionine (Perkin Elmer, #NEG772002MC) in a final volume of 200 µL for 20 mins at 
30°C. The reaction was stopped by adding 750 mM KOAc and 15 mM Mg(OAc)2. The pre-
TCs were immobilized on 200 µL ANTI-FLAG M2 Affinity Gel (SigmaAldrich, #A2220) by 
incubation with gentle rotation at 4°C for 1.5 hours, followed by washing 4X with wash buffer 
1 (50 mM HEPES pH 7.4, 100 mM KOAc, 5 mM Mg(OAc)2, 0.1% Triton X-100, 1mM DTT), 
2X with wash buffer 2 (50 mM HEPES pH 7.4, 250 mM KOAc, 5 mM Mg(OAc)2, 0.5% Triton 
X-100, 1mM DTT) and finally 4X with RNC buffer (50 mM HEPES, pH 7.4, 100 mM KOAc, 5 
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mM Mg(OAc)2, 1mM DTT). The pre-TCs were eluted with 0.1 mg/mL 3xFLAG peptide in RNC 
buffer, aliquoted, flash frozen and stored at -80°C.  
Peptide release assays 
For peptide release assays, [35S]-labelled Pre-TCs were incubated with an equal volume of 
RRL and supplemented with the indicated amount of BlaS. The reactions were incubated at 
30°C for 10 mins, then quenched by the addition of protein SDS-PAGE loading dye. For the 
peptide release time course assays, the reactions were supplemented with 800 nM BlaS and 
incubated at 30°C for the time points indicated. After quenching, the samples were separated 
on a 10% BIS:TRIS PAGE gel. All gels were dried and exposed to a phosphor screen and the 
amount of peptide measured using a Typhoon 9400 Variable Mode Imager (GE 
Healthcare/Amersham Biosciences) and images quantified using ImageJ (28).  
In vitro translation and toeprinting analysis of pre‐ and post‐termination complexes 
In vitro termination and toeprinting analysis were performed as previously described (20). In 
the data displayed in Fig. 1, the release factors or the pre-TCs were incubated for five minutes 
at 37 °C with 5 µg/mL BlaS or 1 mM puromycin (with respect to the final volume of the 
termination reaction) and subsequently combined. Translation termination was performed in 
the presence or absence of UPF3B and allowed to proceed for five minutes. 
In vivo luciferase reporter assay 
The Luciferase reporter system has been described elsewhere (29). Briefly, 1x105 Hela 
cells/well were seeded in 6-well-plates and transfected after 24 hours with 0.6 µg/well of the 
reporter plasmids pCI-Renilla-HBB WT or pCI-Renilla-HBB-Nonsense-Mutation 39 (NS39). 
0.35 µg/well of the pCI-Firefly-luciferase plasmid and 0.2 µg/well of a YFP-expression vector 
were co-transfected for quantification and visual assessment of transfection efficiency. After 
16 hours the cells were washed with full medium and treated for 3 hours with BlaS or left 
untreated as indicated in Fig. 5 and Supplementary Fig 5. Cells were lysed in 200 µl/well 
Passive Lysis Buffer (Promega #E1941). 3 µl were used to measure luciferase luminescence 
in the Centro LB 960 luminometer (Berthold Technologies, Germany) using the Dual-
Luciferase Reporter Assay System (Promega # E1910). Renilla luciferase signals were 
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normalized to the Firefly luciferase control signals and subsequently normalized WT and NS39 
expression levels were compared. In indicated cases transfected cells were lysed in RIPA 
buffer. 10–15 µg of total protein was separated on 10% SDS-PAGE gels and immunoblotted. 
Expression of Renilla-HBB fusion proteins was monitored using an anti-Renilla antibody, and 
Firefly luciferase was detected using an anti-Firefly luciferase antibody (both Merck, 
Darmstadt, Germany). 
Quantitative real-time PCR 
The remainder of above lysate was extracted with TRIzol (ThermoFisher # 15596026) to 
isolate total mRNA. 2 µg total mRNA was used to generate cDNA. The quantitative RT-PCR 
was performed on a StepOnePlus™ machine (Applied Biosystems/ThermoFisher), using 
Absolute™ SYBR green mix (ThermoFisher #AB1158B). The primers used were:  
HBBex1/2sense: 5’CTGGGCAGGCTGCTGGTG3’; HBBex2/3 as: 
5’CGTTGCCCAGGAGCCTGAAG3’; Firefly sense: 5’AGAGATACGCCCTGGTTCCT3’; 
Firefly antisense: 5’ATAAATAACGCGCCCAACAC3’. Renilla-HBB WT/NS39 expression 
levels were normalized to Firefly expression levels and subsequently the normalized Renilla-
HBB-NS39 levels (with and without treatment) were compared to the respective WT levels. 
Sucrose cushion centrifugation and luciferase detection 
A 1mL 1M sucrose cushion in RNC buffer was topped with 300uL of prepared HeLa cell lysate 
transfected as above with pCI-Renilla-HBB-WT, pCI-Renilla-HBB-NS39, or pCI-Firefly-
Luciferase mRNA generated from a 10 cm dish lysed in 20 mM Tris, pH 7.5, 100 mM KAc, 5 
mM Mg(OAc)2, 0.5% NP 40 containing protease and RNase inhibitor. These cells were 
transfected and treated (for 3 hours) with 5 or 100ug/mL BlaS or left untreated and lysed as 
above. Ultracentrifugation was performed at 55,000 rpm for 3 hours using a TLA-55 rotor and 
an Optima Ultracentrifuge (Beckman Coulter) at 4°C.The supernatant was removed, and the 
ribosomal pellet was dissolved in an equal volume RNC buffer. Renilla and Firefly luciferase 
detection was conducted as above using the manufacturers recommended protocol but using 




For statistical analysis SigmaPlot v13 (SyStat Software) was used. Results were considered 
statistically significant if p values were ≤ 0.05, with one star indicating 0.01 < p ≤ 0.05, two 
stars for 0.001 < p ≤ 0.01, and three stars for p ≤ 0.001. Briefly, One-way ANOVAs were 
applied for multiple comparisons (two-tailed), followed by a multiple comparison analysis. The 
statistical analysis was based on at least three replicates with degrees of freedom and 
normality tests detailed in the respective figure legends.  
Cryo-EM sample preparation  
Pre-TCs samples for cryo-EM were prepared as above with the following modifications: The 
in vitro translation reaction volume was increased to 2 mL and supplemented with 20 µg 
capped mRNA and methionine at a final concentration of 50 µM. The reaction was incubated 
at 32°C for 25 minutes. The pre-TCs were incubated for 3 hours with ANTI-FLAG M2 Affinity 
Gel, followed by washing, and eluting twice in 200 µL incubations of 0.1 mg/mL 3xFLAG tag 
peptide in storage buffer at room temp for 25 minutes. Eluted ribosomes were isolated via 0.5 
M sucrose cushion ultracentrifugation (Beckman Coulter TLA-55 rotor, 55,000 rpm, 3 hours, 
4°C). The ribosomal pellets were washed with 100 µL storage buffer before being 
resuspended in 100 µL storage buffer by agitation at 900 rpm at 4°C. Ribosome concentrations 
were determined using the Nanodrop (ThermoFisher, #ND-ONEC-W) and supplemented with 
5X molar excess eRF1AAQ and eRF3a with 1 mM GTP and 5X molar excess BlaS followed by 
ultracentrifugation (Beckman Coulter TLA-120.2 rotor, 100,000xg, 1 hour, 4°C). The pelleted 
ribosomal complexes were resuspended in 50 µL storage buffer and resuspended by agitation 
at 900 rpm at 4°C. Ribosomal concentration as measured and then supplemented with 5X 
molar excess eRF1AAQ and eRF3a with 1 mM GTP and 5X molar excess BlaS (final) prior to 
grid preparation. 
Cryo-EM grids were prepared using 165 nM ribosomal complexes by applying 3 µL sample at 
15⁰C and 70% relative humidity to glow discharged R2/2 quantifoil grids (Electron Microscopy 
Sciences, #Q3100CR2) covered with a ~40 Å thick layer of amorphous carbon prepared using 
a carbon coater (Leica EM ACE 600. Using a Leica EM GP2 plunge freezer, the sample was 
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incubated 30 seconds, blotted for 1.1 seconds, and vitrified in liquid ethane maintained at 
liquid nitrogen temperature. Grids were stored in liquid nitrogen until data collection. 
Data collection and image processing 
Data were collected with a FEI Talos Artica TEM using quasi-automated collection software 
(EPU) equipped with a 200kV X-FEG electron source. Movies were recorded on a K2 Summit 
detector (Gatan) at super-resolution mode, at a dose rate of 5.24 e−/Å2/s with a total exposure 
time of 8 s, for an accumulated dose of 41.9 e−/Å2. Intermediate frames were recorded every 
0.2 s with a total number of 40 movie frames per micrograph. A calibrated magnification of 
100,000x was used yielding a physical pixel size of 1.35 Å (super-resolution pixel size is of 
0.675 Å). Defocus value ranged from −0.4 to −2.0 µm with a step size of 0.4 µm 
(Supplementary Table 1). Movie frames were first aligned using whole-image motion 
correction (30) for reduction of beam-induced image blurring. Micrographs with indications of 
poor contrast, astigmatism, charging, or contamination were discarded. Defocus values of the 
aligned micrographs were estimated using CTFFIND4 (31). Further, micrographs with 
estimated resolutions above 5 Å were discarded. Relion 3.0 (32) was used to manually pick 
particles (approximately 3,500) and generate initial reference-free 2D averages. This was 
followed by automated-picking using Relion 3.0 (32) which yielded a total of 730,463 particles. 
Particle images were extracted with a box size of 600 (binned to 300) yielding a pixel size of 
1.35 Å. 2D class averages were generated and subsequently used to further discard poor 
particles or non-ribosomal particles yielding 295,840 particles. An initial 3D model was 
generated using 50,000 particle images using Relion 3.0 (32). This model was used for further 
3D classifications into eight classes (angular sampling of 7.50 for 5 pixels with local searching 
over 25 iterations) (Supplementary Fig. 2). The five best classes were pooled (255,549 
particles) and subjected to a second round of 3D classification into eight classes (angular 
sampling of 3.50 for 3 pixels with local searching over 25 iterations) and refinement. We 
identified three 3D classes with ribosome bound to BlaS with (1) an empty A-site (Empty-A), 
(2) eRF1 bound A-site (eRF-Bound), and (3) adopting hybrid P/E and A/P tRNA state (Hybrid) 
comprising 103,842, 18,397, and 29,879 particles respectively (Supplementary Fig. 2). 
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Bayesian particle polishing and contrast transfer function (CTF) refinement (33) in Relion 3.0 
(32) resulted in a resolution of 3.13 Å for the Empty-A map (Fourier shell correlation (FSC) 
cut-off 0.143), a resolution of 4.1 Å for the eRF-Bound map, and 3.82 Å for Hybrid map. A b 
factor of −50 was used for map sharpening (the b factor value was determined empirically to 
obtain a well-interpretable density map) (Supplementary Table 1). Local resolution was 
determined using Relion 3.0 (32). 
Model Construction and Refinement  
For the empty A-site model, an 80S ribosome (PDBID: 3JAH (23), without the chains for 
eRF1AAQ and ABCE1) was docked into the map of the empty A-site map using Chimera (34). 
BlaS was modelled using constraints taken from the 70S ribosome structure with BlaS 
(PDBID: 4V9Q (3)), docked into density corresponding to BlaS (using constraints taken from 
ELBO in Phenix using code BLS) using COOT’s ligand fit tool (35,36). Iterative real space 
refinements against the amplitudes and phases from the cryo-EM experimental map (which 
remained unchanged during the refinement) were carried out using Coot (0.8.9.2EL (35)) and 
Phenix (1.17.1-3660 (36)) using blurred maps (B-factors between -25 and -50). The same 
processing steps were utilized for the hybrid A/P-P/E, utilizing PDBID 6HCJ (37) (without 
poly(A) nascent chain and mRNA) as a starting model. For the eRF1/eRF3a-bound model 
PDBID 5LZT (27) was used as a starting model. The quality of the models was scrutinized 







Blasticidin S impact on mammalian translation   
BlaS inhibits translation in prokaryotic and eukaryotic cells and specifically impairs translation 
termination in bacteria (3,4,5). However, detailed biochemical and biophysical studies in a 
mammalian system are lacking. Here, we used an adapted rabbit reticulocyte lysate (RRL) 
translation system for in vitro translation (23) to elucidate the effect of BlaS on eukaryotic 
translation termination. First, we determined the steady state efficiency of translation using a 
luciferase reporter assay in the presence of different BlaS concentrations. Capped Firefly 
luciferase mRNA was added to RRL (23), and synthesis of the luciferase enzyme was 
monitored in a high-throughput plate reader by measuring Luciferin substrate turnover. Upon 
titration of BlaS into the translation reaction, the synthesis of luciferase decreased in a dose-
dependent manner (Fig. 1a). Inhibition of translation was observed at BlaS concentrations as 
low as 5 nM, and translation was completely inhibited by concentrations above 175 nM. The 
half-maximal inhibitory concentration (IC50) was determined to be 21 nM. 
Although our luciferase assay confirmed the overall inhibition of mammalian translation by 
BlaS, it did not inform at which stage translation is affected. To distinguish between translation 
elongation and termination, we used an mRNA encoding an N-terminally 3xFLAG-tagged 
fusion protein consisting of truncated Sec61β furnished with an autonomously folding 15 kDa 
villin head piece (VHP) domain (23) for in vitro translation. Translation of the 3xFLAG-Sec61β-
VHP mRNA in RRL produces a single product that can be detected by Western blot using an 
anti-FLAG antibody (Fig. 1b, lane 6). Addition of an excess (10 µM) of an inactive eRF1 mutant 
(eRF1AAQ) inhibits peptidyl-tRNA hydrolysis by wildtype eRF1, leading to a ribosomal complex 
stalled at the stop codon with peptidyl-tRNA in the P-site and eRF1AAQ in the A-site. 
Accordingly, Western blot analysis of RRL translation reactions in the presence of eRF1AAQ 
revealed, in addition to the band corresponding to the free 3xFLAG-Sec61β-VHP protein, a 
strong band with slower electrophoretic mobility corresponding to unhydrolyzed peptidyl-tRNA 
(Fig. 1b, lane 5). Translation in the presence of 10-200 nM BlaS also produced peptidyl-tRNA 
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bands, but of significantly lower intensity compared to translation in the presence of eRF1AAQ 
(Fig. 1b, compare lanes 1-4 with lane 5). With increasing BlaS concentrations, both the bands 
corresponding to the free and the t-RNA-bound protein decrease in intensity (Fig. 1b, lanes 1-
3). The generation of the peptidyl-tRNA already at low BlaS concentrations and the decrease 
of both the free and tRNA-bound protein at higher BlaS concentrations indicate that in vitro, 
BlaS inhibits mammalian translation both at the elongation and the termination stage.  
 
BlaS inhibits peptide release from the ribosome  
Previous studies using bacterial ribosomes have shown that BlaS inhibits peptide release 
(3,10). To further investigate BlaS’ mode of action in eukaryotes, we performed peptide 
release assays using pre-termination complexes (preTCs) purified from RRL. Because 
tyrosine has been shown to be more efficiently released than valine by release factors in 
bacteria (39) we replaced the valine codon in the penultimate position before the UAG stop 
codon with a tyrosine codon. PreTCs were prepared using this modified 3xFLAG-Sec61β-VHP 
mRNA (3xFLAG-Sec61β-VHP(Tyr)). In vitro translation was performed in the presence of 
[35S]-methionine and eRF1AAQ. Affinity purification via the N-terminal 3xFLAG tag included a 
high-salt wash step to remove all release factors from the preTCs. To investigate peptide 
release in the presence of increasing concentrations of BlaS, wild-type eRFs and GTP were 
added to these preTCs (non-limiting concentrations) and termination proceeded for 10 
minutes. After SDS PAGE and autoradiography, peptidyl-tRNA and free peptide bands were 
quantified (Supplementary Fig. 1). As expected, peptide release decreased with increasing 
BlaS concentrations (Fig. 1c; Supplementary Fig. 1a). The IC50 for peptide release was 
determined to be 120 nM and thus considerably higher than the IC50 determined for translation 
inhibition (21 nM, Fig 1a) indicating that inhibition of termination is only partially responsible 
for BlaS’ effect on translation. 
Next, we explored the time-dependence of peptide release by BlaS. In the presence of eRFs, 
but not BlaS (control reaction), half-maximum peptide release from the pre-TCs was achieved 
within ~4 mins. When the preTCs were pre-incubated with 800 nM BlaS before the addition of 
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eRFs, peptide release was substantially inhibited, and half-maximal release was achieved 
only after 25 mins (Fig. 1d, Supplementary Fig. 1b). 
We could not exclude that BlaS inhibits a step prior to peptide release. Therefore, we tested if 
BlaS also interferes with stop codon recognition by eRF1. Using preTCs that contain a MVHC-
tetrapeptide-tRNA generated in a human reconstituted translation system (20,40), we 
performed primer extension inhibition assays (toeprinting assays). PreTCs with peptidyl‐
tRNACys in the ribosomal P‐site and the stop codon in the A site generate a toe-print band 16 
nucleotides 3’ to the U of the P-site UGC (Cys) codon. Stop codon recognition by eRF1WT or 
eRF1AGQ is detected as a +1 or +2 nucleotide shift from a pre-TC to a post-termination complex 
(postTC) (Fig. 1e, lanes 1,2, Supplementary Fig. 1c) (40). The formation of postTCs, i.e. the 
recognition of the stop codon in the ribosomal decoding center by eRF1, was not impaired by 
the presence of BlaS (Fig. 1e, lanes 3,5,7,8) and/or by the presence of puromycin, which 
causes peptide release (Fig. 1e, left gel, lanes 4,6,7,8). This finding was independent of the 
order of addition of BlaS to the pre-TCs (Fig. 1e, lanes 3,7), or to the eRFs (Fig. 1e, lanes 5,8). 
Thus, BlaS does not interfere with stop codon recognition by eRF1. 
We previously reported that the NMD factor UPF3B dissociates postTCs after peptide release 
by eRFs in a manner reminiscent of ribosome recycling by eIF1, eIF1A, eIF3 and eIF3j (20,41). 
Ribosome dissociation is evidenced by the weakening of postTC toeprints and increased 
intensity of the full-length mRNA band (Fig. 1e, lane 9). When peptide release is further 
enhanced by puromycin, UPF3B causes a disappearance of postTC toeprints indicating 
complete ribosome dissociation (Fig. 1e, lanes 11,13,15). In contrast, BlaS interferes with 
postTC dissociation by UPF3B and preserves postTC toeprints, similar to the eRF1AGQ mutant 
(Fig. 1e, lanes 10,12,14, Supplementary Fig. 1c, compare lanes 5,6,8, and 10). This agrees 
with our finding that BlaS inhibits peptide release (Fig.1c,d), and further confirms our earlier 
finding that UPF3B triggers ribosome dissociation after peptidyl-tRNA hydrolysis. It indicates 
that the efficiency of UPF3B in ribosome dissociation directly reflects the completeness of 
peptide release by puromycin (Fig. 1e, lane 11) or the eRFs (Fig. 1e, lane 9) (20). Interestingly, 
in the toeprinting experiments, pre-binding of BlaS to the preTCs interferes to some extent 
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with peptide release by puromycin and subsequent dissociation of ribosomes by UPF3B (Fig. 
1e, comparing lanes 15 and 14). This may be due to a competition of the two antibiotics for a 
similar binding site reminiscent of the one described in Escherichia coli (42,43), or reflect a 
distortion of the peptidyl transferase center by BlaS interfering with peptide release by 
puromycin. In conclusion, our in vitro termination experiments confirm that BlaS does not 
interfere with stop codon recognition by eRF1 but prevents efficient peptidyl-tRNA hydrolysis 
by the eukaryotic release factors and subsequent ribosome dissociation by UPF3B.  
 
Cryo-EM of mammalian ribosomal termination complexes with BlaS 
In bacteria, archaea, and yeast, BlaS binding occurs in the P-site of the peptidyl transferase 
center of the large ribosomal subunit (3,8-10). In bacterial ribosomes, BlaS binding causes a 
distortion of the 3’CCA tail of the P-site peptidyl-tRNA pushing this region outward in the 
direction of the A-site (3,10). Despite this distortion of the P-site tRNA, BlaS does not prevent 
accommodation of RF1 into the 50S A-site in bacteria (10). To understand BlaS’ impact on 
mammalian translation termination, we solved the cryo-EM structure of ribosomal complexes 
with BlaS, eRF1, and eRF3a in the presence of GTP (Fig. 2). Pre-TCs were generated using 
the RRL in vitro translation system and mRNA encoding 3xFLAG-Sec61β-VHP(Val) described 
above (23). eRF1AAQ was added in excess to the translation reaction to trap termination 
complexes, followed by FLAG affinity purification and extensive wash steps to liberate any 
bound factors including eRF1AAQ from the ribosome. These purified, release factor-free preTCs 
were incubated with 10 µM BlaS and 5X molar excess of eRF1, eRF3a, and 1 mM GTP and 
then used for cryo-grid preparation and EM data collection (Supplementary Fig. 2, 
Supplementary Table 1). 3D classification yielded three major classes: In class 1, called 
‘Empty-A’ (103,842 particles, 3.1 Å resolution), the ribosomal P-site is occupied by peptidyl-
tRNA, and the A-site is free of any bound eRFs (Fig. 2a, Supplementary Figs. 2,3,4, 
Supplementary Table 1). In class 2, called ‘Hybrid’ (29,879 particles, 3.8 Å resolution), tRNAs 
are bound in hybrid P/E and A/P states and no eRFs are bound (Fig. 2b, Supplementary Figs. 
2,3, Supplementary Table 1). In class 3, called ‘eRF-Bound’ (18,937 particles, 4.1 Å 
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resolution), the P-site tRNA is present but poorly resolved (Supplementary Fig. 4c), and 
therefore the P-site tRNA in this structure is not modelled. The A-site in the small subunit (the 
decoding center) is bound by eRF1, and eRF1 and eRF3a are in the pre-accommodation state 
(Fig. 2c, Supplementary Figs. 2,3, Supplementary Table 1) (27). All three structures have BlaS 
bound in the 60S peptidyl transferase center (Fig. 3, Supplementary Fig. 4). 
 
BlaS binding distorts P-site tRNA and prevents eRF1 accommodation 
In the Empty-A cryo-EM structure representing ~35% ribosomes, density for BlaS is observed 
near the 3’CCA tail of the P-site peptidyl-tRNA (Fig. 2d). Hydrogen bonds are formed between 
the cytosine part of BlaS and 28S rRNA bases G4196 and G4197 of the P-loop, but we do not 
observe Watson-Crick base pairing as in bacteria and archaea (3,8). The N-methyl-guanidine 
tail of BlaS interacts with the phosphate backbone of G4385, G4546 and G4547 (Fig. 3). The 
P-site peptidyl-tRNA forms a base-stacking interaction with the cytosine part of BlaS via 
residue A76 of the 3’CCA tail. This leads to displacement of C74 and C75 and distortion of the 
3’CCA end (Fig. 2d, 3a). Interestingly, we observe a van der Waals interaction between BlaS 
and the sidechain of the terminal valine (Val68) of the nascent chain which further contributes 
to BlaS coordination and to distortion of the peptidyl-tRNA (Fig. 3a). Overall, BlaS binding to 
the P-site causes displacements of up to 9.5 Å for backbone phosphates and up to 14.5 Å for 
the bases of the 3’CCA tail of the tRNA relative to their normal position in the P-site of the 
peptidyl transferase center (Fig. 4a) (23). Beyond the 3’CCA tail, the binding of BlaS has 
virtually no impact on the tRNA conformation or the architecture of the 40S decoding center. 
In the Hybrid and eRF-Bound cryo-EM structures, BlaS density is observed in the P-site of the 
60S subunit at the same position (Fig. 3b,c,d). However, small differences are found in the 
positioning of BlaS’ cytosine and N-methyl-guanidine tail resulting in a slightly altered 
hydrogen bonding network and clearer base stacking with both C75 and A76 of the 3’CCA tail 
(Fig. 3b). 
An overlay of A-site and P-site tRNAs from a mammalian ribosomal elongation complex (44), 
with BlaS and peptidyl-tRNA in the Empty-A structure reveals that the distorted P-site tRNA 
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would cause clashes with the A-site tRNA (stars in Fig. 4b). Accordingly, accommodated A-
site aminoacyl-tRNA would have to adopt a different, sub-optimal conformation in the BlaS-
bound ribosome, explaining how BlaS interferes with peptide bond formation and thus 
elongation. 
Structures of bacterial RFs bound to ribosomal complexes have all indicated a strong 
propensity of RFs to exist in the accommodated state (45-48). To determine a cryo-EM 
structure of the pre-accommodation state of the bacterial termination complex, a special 
hyper-accurate RF1 variant combined with termination step inhibition by incubation with BlaS 
was required (49). Eukaryotic termination complexes show eRF1 in the accommodated state 
(23,27,50) and, in the presence of non-hydrolysable GTP analogues, in the pre-
accommodated state (27,51). Our three cryo-EM structures all show an empty 60S A-site 
despite efficient stop codon recognition by eRF1 in toeprinting assays (Fig. 1e, Fig. 2). This 
was unexpected because we added excess GTP to our sample and thus stop codon 
recognition should lead to activation of eRF3a, GTP hydrolysis, and accommodation of eRF1 
into the A-site of the peptidyl transferase center. However, density for eRF1 was found only in 
the decoding center of 40S in one of the structures (Fig. 2c). This eRF-bound structure, which 
presents ~6% of the particles, is lower resolution (4.1 Å) compared to the other two structures, 
and the local resolution of eRF1 and eRF3a is even lower (ca 4.5-6.0 Å), suggestive of a 
degree of dynamic conformational sampling within the eRF1-eRF3a complex (Supplementary 
Fig. 3c). This likely reflects attempted accommodation by eRF1 which is being prevented by 
BlaS binding. An overlay of a previous mammalian ribosomal termination complex with 
accommodated eRF1 (27) with our Empty-A structure reveals a steric clash between the 
distorted 3’CCA tail of the BlaS-bound peptidyl-tRNA and the M domain of eRF1, including the 
catalytic GGQ motif of eRF1 responsible for peptide release (Fig. 4c). In contrast, a structure 
of a bacterial 70S termination complex bound to RF1 and BlaS showed accommodation of 
RF1 (10), but with distortion of the catalytic GGQ motif of RF1. This difference is most likely 
due to a substantially larger distortion of the mammalian peptidyl-tRNA in the presence of BlaS 
compared to bacterial tRNA in the P-site (3) (Fig. 4d). BlaS is localized further towards the 3’ 
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end of the tRNA in the mammalian complex, closer to the site of the nucleophilic attack, 
potentially explaining the observed larger shift in the 3’CCA tail. This difference in distortion of 
the P-site tRNA may allow accommodation of bacterial RF1 but not of eRF1. Therefore, the 
absence of eRF1 accommodation in our structures is likely explained by this comparatively 
large distortion of the 3’CCA tail of peptidyl-tRNA. Consequently, the steric clash in this case 
is much more severe, interfering with eRF1 accommodation into the peptidyl transferase 
center in the presence of BlaS and subsequent peptide release. 
 
Sub-inhibitory BlaS concentrations moderately stabilize nonsense mRNA and induce 
production of a truncated protein 
Translation termination is thought to differ between normal and nonsense-mutated mRNAs. 
However, no assays to assess translation termination mechanisms in vivo are available to 
date. Because BlaS delays peptide release in vitro, we hypothesized that a similar activity of 
BlaS in vivo may resemble delay of termination at a nonsense codon, thus further enhancing 
assembly of the NMD machinery and possibly decay of an NMD substrate reporter mRNA, or 
even triggering decay of the corresponding WT mRNA. In contrast, since NMD is a translation-
dependent process, inhibition of translation initiation or elongation prevents NMD and 
stabilizes premature stop codon-containing mRNAs (15,16,52,53). We used our 
chemiluminescence-based NMD reporter system (29) to investigate (i) whether translation 
inhibition by BlaS could be observed in vivo and (ii) if BlaS treatment exerted a specific effect 
on the expression of the WT and nonsense-mutated reporter mRNAs. HeLa cells were 
transfected with reporter constructs comprising a Renilla luciferase open reading frame (ORF) 
N-terminally fused to the human β-globin (HBB) gene with or without a premature stop codon 
at position 39 in exon 2 of the HBB ORF (Renilla-HBB WT/NS39). Co-transfection and co-
expression of Firefly luciferase served as quantification control of both mRNA and protein 
expression (29) (Supplementary Fig. 5). Messenger RNA levels were quantified by qRT-PCR 
(Fig. 5a). Protein expression was monitored by Western Blot (Supplementary Fig. 5a) and by 
chemiluminescence, measuring enzymatic activity of the produced luciferases (Fig. 5b). In 
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HeLa cells transfected with the Renilla-HBB NS39 plasmid and treated with BlaS for 3 hours, 
we observed a BlaS concentration-dependent increase of the reporter mRNA levels (Fig. 5a 
right), whereas levels of the WT mRNA remained unchanged (Fig. 5a left). This suggests that 
inhibition of translation termination by BlaS was either not efficient in vivo or failed to simulate 
the molecular context of termination at a premature stop codon and thus did not lead to mRNA 
decay. 
 
Interestingly, Renilla luciferase enzymatic activity expressed from the nonsense reporter 
mRNA increased ~1.8-fold in the presence of 5 and 10 µg/mL BlaS (Fig. 5b right) whereas the 
levels of luciferase expressed from the Renilla-HBB WT mRNA had no statistically significant 
change (~1.2-fold, Fig. 5b left). At the same time, as judged by the expression of Firefly 
luciferase and actin B protein controls, global translation was not substantially affected at 5-
10 µg/mL BlaS (Supplementary Fig. 5a). The increased production of the Renilla-HBB 
nonsense protein is consistent with a similarly elevated nonsense mRNA level at 5-10 µg/mL 
BlaS (Fig. 5a right). Thus, the observed increase of both protein and nonsense mRNA levels, 
indicates that partial inhibition of NMD leads to higher nonsense mRNA level and increased 
translation of the encoded truncated protein. In contrast, higher concentrations of BlaS (50 
and 100 µg/mL BlaS) considerably reduce protein production and enzymatic activity of both 
the Renilla-HBB WT and nonsense reporter while inhibiting NMD as reflected by the up to 4-
fold increased expression of the nonsense reporter mRNA up to ~80% of the WT mRNA level 
(Fig.5a,b). Taken together, this suggests that stabilization of nonsense mRNAs by BlaS 
treatment precedes complete translation inhibition. 
 
BlaS does not prevent nascent chain release in vivo 
We hypothesized that inhibition of translation termination by BlaS would lead to an 
accumulation of ribosome-associated nascent protein in vivo. In eukaryotes, depending on co-
translational folding of the nascent peptide the ribosomal exit tunnel covers ~30–70 amino 
acid residues of the growing peptide chain (54). Firefly luciferase C-terminally extended by a 
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respective number of amino acid residues can be enzymatically active while still associated 
with the ribosome whereas luciferase without C-terminal extension is only active after release 
from the ribosome (55). In our reporter system, the Renilla luciferase portion of the Renilla-
HBB-WT and NS39 proteins contain C-terminal extensions of 149 and 41 amino acids, 
respectively (29). For β-globin the average peptide length covered by the exit tunnel has been 
determined in an RRL system to be 30-35 amino acids (56). Therefore, we reasoned that 
ribosome-bound Renilla-HBB-NS39 nascent protein can only be active if translation inhibition 
occurs at or very close to the premature stop codon. By contrast, Renilla luciferase expressed 
from the Renilla-HBB-WT mRNA can metabolize its substrate as soon as the Renilla part of 
the fusion protein has fully emerged from the ribosome and therefore also when translation 
stalls during elongation within most of the HBB ORF. Using sucrose cushion centrifugation, 
we investigated the activity of ribosome-associated and released Renilla luciferase expressed 
from Renilla-HBB-WT or -NS39 mRNA in the presence of sub-inhibitory or inhibitory 
concentrations of BlaS (Fig. 5c). HeLa cells were transfected with Renilla-HBB-WT or Renilla-
HBB-NS39 encoding plasmids, and the Firefly luciferase encoding control plasmid and treated 
with two concentrations of BlaS (5 and 100 µg/mL) or were left untreated. Cytoplasmic lysates 
were loaded onto 1M sucrose cushions, ultracentrifuged and ribosome-containing pellets (P) 
and ribosome-free supernatant fractions (SNT) were collected to measure the relative 
luciferase activity (Fig. 5c). Firefly luciferase that carries no C-terminal extension as expected 
displayed only background activity in the ribosomal pellet (Supplementary Fig. 5c). Renilla-
HBB WT and -NS39 luciferase activity was significantly reduced when treated with high, 
inhibitory concentrations of BlaS (Fig. 5c) in both ribosome-containing and ribosome-free 
fractions. By contrast, in the soluble fraction, sub-inhibitory concentrations of BlaS (5 µg/mL) 
as before resulted in ~1.8-fold activity increase of Renilla-HBB-NS39 relative to the untreated 
sample (Fig. 5c right), while in Renilla-HBB WT protein expression remained largely 
unchanged (Fig. 5c left). Notably, the vast majority of both WT and NS39-mutated 
enzymatically active Renilla-HBB protein was found in the ribosome-free fraction, whereas 
only a minor portion of both were ribosome-associated irrespective of the treatment. This 
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Although BlaS was discovered to inhibit protein synthesis as early as in the 1960’s, its 
functional characterization has hitherto been largely limited to bacterial and fungal systems 
(3-6,10,42,43). We expected BlaS’ mode of action and hence the preferential inhibition of 
translation termination to be conserved in Mammalia. Importantly, a specific inhibitor of 
termination would be an attractive tool to study the link between translation termination and 
NMD in vivo in higher eukaryotes. We therefore investigated the mechanism of BlaS-mediated 
inhibition of mammalian translation biochemically and structurally. 
Similar to the situation in bacteria, we found that BlaS slows down peptide release mediated 
by eRF1, eRF3a and GTP and partially prevents peptidyl-tRNA hydrolysis. At higher 
concentrations BlaS inhibits peptide synthesis (Fig. 1b), revealing an impact on both 
elongation and termination steps. However, in our mammalian system, translation termination 
is impaired at a 6-fold higher concentration than elongation (IC50 21 nM for translation inhibition 
vs 120 nM for termination inhibition, Fig. 1a,c), while the situation in bacteria is the reverse 
(IC50 182-380 nM vs 32 nM) (3,43). Hence, our in vitro experiments indicate that BlaS inhibits 
elongation more efficiently than peptide release in Mammalia (Fig. 1a,c). Consistently, a recent 
study using an adapted luciferase system to monitor in vitro mammalian translation termination 
in real-time reported that BlaS (at high concentration) strongly inhibits translation elongation 
(55). However, the authors found no effect on termination (55). We further explored specific 
steps of termination, and found that stop codon recognition by the eRFs, a precondition of 
eRF1-mediated peptide release, is not affected by BlaS (Fig. 1e left, Supplementary Fig. 1c). 
UPF3B-mediated ribosome dissociation, which requires peptide release, is impaired in the 
presence of BlaS (Fig. 1e, right), thus confirming that BlaS inhibits the peptide release step 
during translation termination. 
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To better understand BlaS’ mode of action regarding mammalian peptide release, we solved 
the cryo-EM structure of ribosomal termination complexes in the presence of BlaS, eRFs and 
GTP. Our findings illuminate the differences between the effects of BlaS on bacterial versus 
mammalian translation. Computational sorting yielded three distinct complexes which all 
comprised BlaS density bound to the P-loop in the peptidyl transferase center. BlaS displaces 
both C74 and C75 of the 3’CCA tail from the rRNA (Fig. 4a). In contrast, in the bacterial BlaS-
ribosome structures only C75 is displaced by ~7Å by BlaS which intercalates between C74 
and A76 (Fig. 4d) (3,10). In our structure, BlaS displaces C74 and C75 up to 14.5 Å resulting 
in a substantially larger distortion in the peptidyl transferase center (Fig. 4a). 
Our structures shed light on the mechanism of BlaS’ inhibition of peptide bond formation and 
peptide release. The displacement of the peptidyl-tRNA from the P-loop towards the A-site is 
predicted to lead to a series of clashes with the amino acyl-tRNA bound to the A-site (Fig. 4b). 
Accommodation of amino-acyl-tRNA into the A-site would require a conformational adaptation 
resulting in suboptimal geometry of the tRNAs and thus slowdown of the peptidyl transfer 
reaction. In the eRF-Bound termination complex, eRF1 is bound in the pre-accommodated 
state and complexed with eRF3a (Fig. 2c). The lower local resolution of the eRFs (4.5-6.0Å) 
and the flexibility of the P-site tRNA (only weak density for the 3’CCA tail and anticodon stem 
loop is detected) suggests that these factors are in a state of conformational sampling, likely 
a product of attempted accommodation of eRF1. Superimposition of the Empty-A structure 
with a termination complex with bound, accommodated eRF1 (27) reveals a substantial steric 
clash between the GGQ-loop of eRF1 and the displaced 3’CCA tail of the P-site tRNA (Fig. 
4c). This indicates that eRF1 accommodation into the peptidyl transferase center is inhibited 
in the presence of BlaS. In contrast, RF1 accommodation in the bacterial ribosome in the 
presence of BlaS is enabled due to a ~2Å shift of the GGQ-motif of RF1 and a distortion of the 
conserved U2585 residue (bacterial rRNA numbering) which then binds Gln235 of the GGQ 
motif (10). Consequently, the interaction between RF1 and peptidyl-tRNA is perturbed and 
this leads to inhibition of peptide release. In our structures, the 3’CCA tail of P-site tRNA is 
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shifted even further (~14.5Å, compared to ~7Å) towards the A-site, likely preventing eRF1 
accommodation into the 60S A-site (Fig 4c,d). 
Because purified ribosomes and translation factors only partially recapitulate the situation in a 
cellular environment, we used our NMD reporter system (29) to address the impact of a range 
of BlaS concentrations on translation of a normal and a premature stop codon-mutated 
transcript in transiently transfected HeLa cells. Specifically, we wondered whether the 
termination inhibition activity of BlaS would enhance mRNA decay as reflected by both mRNA 
level and enzymatic reporter activity and thus support a model of NMD where delayed 
termination triggers mRNA decay (11-13,17). However, while the WT reporter mRNA level 
remained unaffected by BlaS, the premature stop codon-mutated mRNA level gradually 
increased with increasing BlaS concentrations to 80% of the WT at the highest concentration 
tested. At this concentration both WT and truncated protein expression and activity were 
considerably reduced (Fig. 5a,b). NMD inhibition by translation inhibitors is well-described 
(15,16,52,57-59). It therefore appears that BlaS mainly acts as an elongation inhibitor in vivo. 
Interestingly, protein expression from Renilla luciferase-HBB wildtype and nonsense reporter 
mRNAs, as measured by enzymatic activity, differed in response to BlaS treatment (Fig. 5b): 
At sub-inhibitory concentrations, wildtype protein expression was virtually unaffected by BlaS 
(~1.2-fold) and only inhibited at high concentrations. In contrast, sub-inhibitory concentrations 
of BlaS induced an increase of both expression and activity of the truncated reporter protein 
(Fig. 5b, right panel; Supplementary Fig. 5), while global translation seems not to be affected 
under these conditions. Our sucrose centrifugation experiments revealed that neither full-
length nor truncated Renilla-HBB nascent chains accumulate on elongation- or termination-
stalled ribosomes after BlaS treatment. It thus appears that either termination is not 
significantly inhibited at these BlaS concentrations or that in vivo stalled ribosomes are rapidly 
dissolved and the produced nonsense proteins are released from the ribosome (Fig. 5c). We 
note that the stimulatory effect on nonsense protein expression at sub-inhibitory BlaS 
concentrations appears to be proportional to the stabilization of the nonsense mRNA levels 
(Fig. 5a,b); both mRNA and protein enzymatic activity increased ~1.8-fold at 5 and 10 µg/mL 
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BlaS. In conclusion, NMD appears to be sensitive to small disturbances of translation 
dynamics by antibiotics. 
In recent years, translation inhibitors were used to study no-go decay and ribosome quality 
control mechanisms (37,60). Subinhibitory cycloheximide concentrations induce ribosome 
collisions and trigger no-go quality control (60). Ribosome collisions induced by difficult-to-
translate sequences (e.g. by poly(A) sequences) and subsequent translational quality control 
can be prevented by sub-inhibitory amounts of initiation inhibitor pactamycin leading to a lower 
ribosome density on the mRNA transcript; and this slowdown of translation through a 
problematic sequence does not cause ribosome collisions (37). Here, the sub-inhibitory BlaS 
concentrations are likely to slow-down elongation by binding and dissociating from the 
ribosome. At the same time, this mildly impaired elongation may prevent translation 
termination at the premature stop codon from being recognized as slow and aberrant, and 
therefore NMD is not triggered. It seems that by generating a translation problem elsewhere 
(during elongation), problems during termination can be avoided, possibly by reducing 
ribosomal collisions at the premature stop codon. This suggests that the NMD machinery can 
be impaired by the absence of active translation (global translation inhibition) as well as by 
changed translation dynamics (slowed elongation). 
Further investigation is required to understand how cells use such translation dynamics to 
finetune the levels of endogenous NMD-target mRNAs. Enhanced expression of proteins 
encoded by exogenous and endogenous NMD target mRNAs has been observed upon 
treatment with other NMD inhibitors (59). Moreover, the extent of nonsense mRNA 
stabilization in response to antibiotics treatment varies depending on NMD substrate and cell 
type (61,62). Further studies will reveal if such antibiotics-induced effects could be exploited 
for new treatment strategies of NMD-associated diseases, where NMD aggravates the 






The ribosome maps have been deposited to the EMDB with accession codes EMD-12633 
(Empty-A), EMD-12631 (Hybrid) and EMD-12632 (eRF-Bound). Atomic coordinates have 
been deposited to the Protein Data Bank under accession codes PDB 7NWI (Empty-A), 
7NWG (Hybrid) and 7NWH (eRF-Bound). All other data are available upon request.  
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Figure 1: BlaS inhibitory effects on mammalian translation. a, BlaS’ impact on in vitro 
translation determined via luciferase activity. Normalized response units are plotted against 
BlaS concentrations. b, Immunoblot using anti-FLAG antibody to detect free peptide (lower 
band) and peptidyl-tRNA (upper band). Translation termination was inhibited by addition of 
10 µM eRF1AAQ and different BlaS concentrations as indicated. c, Peptide release of [35S]-
methionine labelled 3xFLAG-Sec61β-VHP(Tyr) peptide from the ribosome in the presence of 
increasing concentrations of BlaS. Addition of BlaS decreases the ratio of free peptide 
compared to peptidyl-tRNA.  d, Time-dependence of peptide release inhibition by BlaS. The 
ratio of released peptide vs peptidyl-tRNA is determined in the absence (squares) and 
presence (dots) of 800 nM BlaS.  e, Left autoradiogram: Toeprinting analysis of ribosomal 
complexes obtained by incubating preTC assembled on MVHC-stop mRNA (MVHC-preTCs) 
with eRF1, eRF3a, GTP, and combinations of 5 µg/mL BlaS and 1 mM puromycin at 1 mM 
free Mg2+. The positions of preTCs, postTCs and full-length cDNA are indicated. Asterisks 
mark initiation and elongation complexes. Right: Toeprinting analysis of ribosomal complexes 
obtained by incubating preTCs with UPF3B, eRF1, eRF3a, GTP, and combinations of 5 µg/mL 
BlaS and 1 mM puromycin. Disappearance of the postTC band indicates dissociation of 
ribosomal complexes and concomitant release of mRNA, as indicated by more full-length 
cDNA. The gel on the left was exposed 2x longer than gel on the right.The slightly lower 
intensity of the postTC toe-print band generated after incubation with puromycin (lanes 4,6,8) 
is likely due to puromycin-treated pre-TCs being relatively unstable at the low Mg2+ 
concentrations used (63). Error bars indicate the standard deviation of three replicates.  
 
Figure 2: Cryo-EM structures of mammalian termination complexes (TC) with BlaS. 
Three major classes were identified in our data. a, TC-structure with empty A-site and with 
BlaS and peptidyl-tRNA bound to the P-site (Empty-A, 3.1 Å resolution) representing ~35% of 
the particles. b, Structure with BlaS, empty tRNA in the P/E hybrid state and peptidyl-tRNA in 
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the A/P hybrid state (Hybrid, 3.8 Å resolution) representing ~11% of the particles. c, TC-
structure with BlaS in the peptidyl transferase center and eRF1/eRF3a in a pre-
accommodation state bound to the decoding center of 40S (eRF-Bound, 4.1 Å resolution) 
representing ~6% of the particles. In panels a-c, the 60S subunit is depicted in cyan, the 40S 
in orange, mRNA in red, nascent chain in grey, peptidyl-tRNA in green, empty tRNA in light 
red, eRF1 in pink, eRF3a in magenta, and BlaS in purple. d, Close-up view into the peptidyl 
transferase center in the Empty-A structure. EM density (purple mesh) corresponding to BlaS 
(purple) bound to 28S rRNA (cyan) and by the 3’ CCA tail of the P-site peptidyl-tRNA (green, 
nascent chain grey) is shown. Left: same view as in panel a; right: 100° rotated about the Y-
axis.  
 
Figure 3: BlaS binding to the P-site in the 60S peptidyl transferase center. Contacts 
formed by BlaS (purple) with 28S rRNA bases in the P-site (cyan) and with the 3’CCA tail of 
the bound peptidyl-tRNA (green and grey for nascent chain) in the Empty-A structure (a), the 
Hybrid structure (b) and the eRF-Bound structure (c). Hydrogen bonds are shown by black 
dashed lines, van der Waals contacts are shown by grey dotted lines. d, The relative positions 
and orientations of bound BlaS in these three structures are overlaid with BlaS colored 
magenta in the Empty-A structure, pink in the Hybrid structure, and light pink in the eRF-
Bound structure. 
 
Figure 4: Mis-positioning of the peptidyl-tRNA 3’CCA tail in the presence of BlaS.  a, 
Overlay of BlaS-bound P-site tRNA in the Empty-A structure (light green, BlaS purple) and P-
site tRNA in a normal (not BlaS-bound) mammalian ribosomal termination complex (dark 
green) (PDBID: 3JAH, (23)). Arrows indicate displacement of the 3’CCA bases. b, Overlay of 
BlaS-bound P-site tRNA in the Empty-A structure (light green, BlaS purple) and of an 
elongating Thermus thermophilus 70S ribosomal complex with acylated A-site (pink) and P-
site tRNAs (grey) (PDBID: 4V5D, (44)). Minor steric clashes are indicated by yellow stars.  c, 
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Comparison of BlaS-bound P-site tRNA in the Empty-A structure (light green, BlaS purple) 
with the structure of the mammalian termination complex with eRF1 accommodated in the A-
site (PDBID: 5LZU, (27)). The P-site tRNA in the termination complex was omitted for clarity. 
Severe steric clashes are indicated in orange. d, Comparison of BlaS-bound bound P-site 
tRNA in the Empty-A structure (light green, BlaS magenta) with the crystal structure of Th. 
thermophilus 70S ribosome-tRNA complex (dark red) bound to Blas (pink) (PDBID: 4V9Q, (3)) 
showing differences in BlaS binding to bacterial and eukaryotic ribosomal complexes. These 
result in larger distortion of the tRNA 3’CCA tail in the mammalian complex. The structures 
were aligned for the 28S (23S in panel d) rRNA residues (not shown for clarity).  
 
Figure 5: Quantification of Renilla-HBB reporter mRNA levels and associated luciferase 
activity in transfected HeLa cells after incubation with different concentrations of BlaS. 
a, qRT-PCR analysis of the Renilla-HBB wildtype reporter mRNA (left) and of the Renilla HBB 
NS39 reporter mRNA (right), following treatment with indicated BlaS concentrations. The 
levels of reporter mRNA are shown as percentage of Renilla-HBB WT mRNA not treated with 
BlaS (0 µg/mL BlaS), with the SD of three or more independent experiments. Co-expressed 
Firefly luciferase mRNA levels was used to normalize the levels of Renilla-HBB mRNA. b, 
Reporter luciferase activity following treatment with indicated BlaS concentrations, normalized 
to wildtype Renilla luciferase-HBB activity not treated with BlaS (0 µg/mL BlaS), with the SD 
of three or more independent experiments. c, Reporter luciferase activity following treatment 
of transfected cells with two indicated concentrations of BlaS and sucrose cushion 
centrifugation. Left: supernatant fraction, right: ribosomal pellet fraction. Luciferase activity of 
the Renilla-HBB WT reporter is shown in grey; luciferase activity of the Renilla-HBB NS39 
reporter in black. The activity of Renilla-HBB reporter protein is normalized to Renilla-HBB WT 
protein sample not treated with BlaS (0 µg/mL BlaS), with the SD of three or more independent 
experiments. One-way ANOVA’s (Holm-Šidák) statistical significance tests (α=0.05) are 
indicated with asterisks identifying those with a p value 0.01 < p ≤ 0.05 having one, 0.001 < p 
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≤ 0.01, and three for p ≤ 0.001.  Panel a denoting mRNA and panel b for associated luciferase 
measurements had 3 measurements per triplicate resulting in degrees of freedom (DF) of 47. 
Panel b denoting luciferase measurements from sucrose cushions had 7 measurements per 
triplicate yielding DF=62. Normality of distributions was assessed via Shapiro Wilk tests for 
each panel with p=0.058 and p=0.180, p=0.671 and p=0.783, p=0.073 and p=0.077 for mRNA, 
luciferase, and sucrose-luciferase right and left panels, respectively. 
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